The world’s largest serum manufacturer, Serum Institute of India Pvt. Ltd, (Serum), has established a formal collaborative partnership with Aragen Bioscience Inc., a subsidiary unit of GVK BIO and one of the leading pre-clinical CROs specializing in monoclonal antibody and other larger-molecule product development to develop multiple stable cell lines to support Serum’s HIV program. Both organizations are aligned and seek to come through with a goal of developing affordable monoclonal antibodies that improve quality of human life.
What will Aragen leverage in this partnership? Serum?
Aragen will leverage its expertise with their RapTr™ platform for utilizing proprietary vectors and CHO DG44 host cells to develop the cell lines. Combined with the analytics platform, Aragen is set to offer Seum with high expressing cell lines enabling Serum to expeditiously progress their program into manufacturing. On the other hand, Seum will focus its efforts progressing select novel molecules into impactful vaccines or therapies and hence support the prevention of diseases around the world.
Who is GVK Bio?
GVK Bio is a leading contract research & development organization servicing the global life sciences industry including Aragen Bioscience, Inc., in California. Formed in 2001, they have over 19 years of experience across the R&D value chain with a focus on speed and quality while working to ensure the highest safety and compliance. GVK Bio has a team of over 2,500 highly qualified scientists, backed by a non-conflict of interest business model, well-defined and scalable processes, modern facilities and a strong customer-centric partnering approach.
Who is Serum?
Serum Institute of India Pvt. Ltd. was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics. Serum is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe. Serum is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized lifesaving biologics like vaccines using cutting edge genetic and cell-based technologies, antisera and other medical specialties. The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.